ID   SAHH2_HUMAN             Reviewed;         530 AA.
AC   O43865; B4E168; Q2TAJ6; Q502W8; Q5VSM0; Q6P171; Q96PK4; Q9UG84;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   04-APR-2006, sequence version 2.
DT   10-MAY-2017, entry version 166.
DE   RecName: Full=S-adenosylhomocysteine hydrolase-like protein 1 {ECO:0000312|HGNC:HGNC:344};
DE   AltName: Full=DC-expressed AHCY-like molecule;
DE   AltName: Full=IP(3)Rs binding protein released with IP(3);
DE            Short=IRBIT;
DE   AltName: Full=Putative adenosylhomocysteinase 2;
DE   AltName: Full=S-adenosyl-L-homocysteine hydrolase 2;
DE            Short=AdoHcyase 2;
GN   Name=AHCYL1 {ECO:0000312|HGNC:HGNC:344};
GN   Synonyms=DCAL, IRBIT, XPVKONA {ECO:0000312|HGNC:HGNC:344};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   DEVELOPMENTAL STAGE.
RX   PubMed=11904675; DOI=10.1007/s00251-001-0402-z;
RA   Dekker J.W., Budhia S., Angel N.Z., Cooper B.J., Clark G.J.,
RA   Hart D.N., Kato M.;
RT   "Identification of an S-adenosylhomocysteine hydrolase-like transcript
RT   induced during dendritic cell differentiation.";
RL   Immunogenetics 53:993-1001(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Kidney, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 48-251 (ISOFORM 2).
RC   TISSUE=Brain, Colon, Eye, Placenta, PNS, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 16-530 (ISOFORM 1).
RC   TISSUE=Skin;
RA   Volpe J.P.G., McDowell M., Jostes R.F., Afzal V., Sadinski W.,
RA   Trask B.J., Legerski R., Cleaver J.E.;
RT   "Complementation of chromosomal instability in the xeroderma
RT   pigmentosum variant by a gene on human chromosome 1 with homology to
RT   S-adenosyl homocysteine hydrolase.";
RL   Submitted (DEC-1996) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 48-164 (ISOFORM 2).
RC   TISSUE=Chondrocyte;
RX   PubMed=12878157; DOI=10.1016/S0014-4827(03)00130-7;
RA   Imabayashi H., Mori T., Gojo S., Kiyono T., Sugiyama T., Irie R.,
RA   Isogai T., Hata J., Toyama Y., Umezawa A.;
RT   "Redifferentiation of dedifferentiated chondrocytes and chondrogenesis
RT   of human bone marrow stromal cells via chondrosphere formation with
RT   expression profiling by large-scale cDNA analysis.";
RL   Exp. Cell Res. 288:35-50(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 48-105 (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=7782076; DOI=10.1016/0888-7543(95)80096-5;
RA   Pawlak A., Toussaint C., Levy I., Bulle F., Poyard M., Barouki R.,
RA   Guellaen G.;
RT   "Characterization of a large population of mRNAs from human testis.";
RL   Genomics 26:151-158(1995).
RN   [10]
RP   IDENTIFICATION (ISOFORM 2).
RX   PubMed=16754674; DOI=10.1074/jbc.M602520200;
RA   Cooper B.J., Key B., Carter A., Angel N.Z., Hart D.N.J., Kato M.;
RT   "Suppression and overexpression of adenosylhomocysteine hydrolase-like
RT   protein 1 (AHCYL1) influences zebrafish embryo development: a possible
RT   role for AHCYL1 in inositol phospholipid signaling.";
RL   J. Biol. Chem. 281:22471-22484(2006).
RN   [11]
RP   FUNCTION, SUBUNIT, INTERACTION WITH ITPR1, PHOSPHORYLATION AT SER-68
RP   AND SER-71, AND MUTAGENESIS OF SER-64; SER-66; SER-68; SER-70; SER-71;
RP   THR-72; SER-74; SER-76; SER-77; SER-80; THR-82; SER-84; SER-85; SER-90
RP   AND THR-97.
RX   PubMed=16793548; DOI=10.1016/j.molcel.2006.05.017;
RA   Ando H., Mizutani A., Kiefer H., Tsuzurugi D., Michikawa T.,
RA   Mikoshiba K.;
RT   "IRBIT suppresses IP3 receptor activity by competing with IP3 for the
RT   common binding site on the IP3 receptor.";
RL   Mol. Cell 22:795-806(2006).
RN   [12]
RP   FUNCTION, INTERACTION WITH SLC4A4, AND MUTAGENESIS OF THR-52; THR-58;
RP   SER-62; SER-64; SER-66; SER-68; SER-70; SER-71; THR-72; SER-74;
RP   SER-76; SER-77; SER-80; THR-82; SER-84; SER-85; SER-90 AND THR-97.
RX   PubMed=16769890; DOI=10.1073/pnas.0602250103;
RA   Shirakabe K., Priori G., Yamada H., Ando H., Horita S., Fujita T.,
RA   Fujimoto I., Mizutani A., Seki G., Mikoshiba K.;
RT   "IRBIT, an inositol 1,4,5-trisphosphate receptor-binding protein,
RT   specifically binds to and activates pancreas-type Na+/HCO3-
RT   cotransporter 1 (pNBC1).";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:9542-9547(2006).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH SLC9A3.
RX   PubMed=18829453; DOI=10.1074/jbc.M805534200;
RA   He P., Zhang H., Yun C.C.;
RT   "IRBIT, inositol 1,4,5-triphosphate (IP3) receptor-binding protein
RT   released with IP3, binds Na+/H+ exchanger NHE3 and activates NHE3
RT   activity in response to calcium.";
RL   J. Biol. Chem. 283:33544-33553(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-391, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   FUNCTION, INTERACTION WITH FIP1L1 AND PAPOLA, RNA-BINDING, AND
RP   MUTAGENESIS OF SER-62; SER-64; SER-66; SER-68; SER-70; SER-71; THR-72;
RP   SER-74; SER-76; SER-77; SER-80; THR-82; SER-84; SER-85; SER-90 AND
RP   THR-97.
RX   PubMed=19224921; DOI=10.1074/jbc.M807136200;
RA   Kiefer H., Mizutani A., Iemura S., Natsume T., Ando H., Kuroda Y.,
RA   Mikoshiba K.;
RT   "Inositol 1,4,5-triphosphate receptor-binding protein released with
RT   inositol 1,4,5-triphosphate (IRBIT) associates with components of the
RT   mRNA 3' processing machinery in a phosphorylation-dependent manner and
RT   inhibits polyadenylation.";
RL   J. Biol. Chem. 284:10694-10705(2009).
RN   [16]
RP   INTERACTION WITH AHCYL2 AND ITPR1, AND PHOSPHORYLATION AT SER-68;
RP   SER-71; SER-74 AND SER-77.
RX   PubMed=19220705; DOI=10.1111/j.1471-4159.2009.05979.x;
RA   Ando H., Mizutani A., Mikoshiba K.;
RT   "An IRBIT homologue lacks binding activity to inositol 1,4,5-
RT   trisphosphate receptor due to the unique N-terminal appendage.";
RL   J. Neurochem. 109:539-550(2009).
RN   [17]
RP   FUNCTION, INTERACTION WITH SLC9A3, AND MUTAGENESIS OF SER-68; SER-71
RP   AND SER-74.
RX   PubMed=20584908; DOI=10.1074/jbc.M110.133066;
RA   He P., Klein J., Yun C.C.;
RT   "Activation of Na+/H+ exchanger NHE3 by angiotensin II is mediated by
RT   inositol 1,4,5-triphosphate (IP3) receptor-binding protein released
RT   with IP3 (IRBIT) and Ca2+/calmodulin-dependent protein kinase II.";
RL   J. Biol. Chem. 285:27869-27878(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR METHIONINE [LARGE
RP   SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [20]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1 (ISOFORM 2), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.64 ANGSTROMS) OF 89-530 OF MUTANT ALA-508 IN
RP   COMPLEX WITH NAD, COFACTOR, FUNCTION, INTERACTION WITH RRM1,
RP   MISCELLANEOUS, PEST REGION, AND PHOSPHORYLATION.
RX   PubMed=25237103; DOI=10.1126/science.1251550;
RA   Arnaoutov A., Dasso M.;
RT   "Enzyme regulation. IRBIT is a novel regulator of ribonucleotide
RT   reductase in higher eukaryotes.";
RL   Science 345:1512-1515(2014).
CC   -!- FUNCTION: Multifaceted cellular regulator which coordinates
CC       several essential cellular functions including regulation of
CC       epithelial HCO3(-) and fluid secretion, mRNA processing and DNA
CC       replication. Regulates ITPR1 sensitivity to inositol 1,4,5-
CC       trisphosphate competing for the common binding site and acting as
CC       endogenous 'pseudoligand' whose inhibitory activity can be
CC       modulated by its phosphorylation status. In the pancreatic and
CC       salivary ducts, at resting state, attenuates inositol 1,4,5-
CC       trisphosphate-induced calcium release by interacting with ITPR1
CC       (PubMed:16793548). When extracellular stimuli induce ITPR1
CC       phosphorylation or inositol 1,4,5-trisphosphate production,
CC       dissociates of ITPR1 to interact with CFTR and SLC26A6 mediating
CC       their synergistic activation by calcium and cAMP that stimulates
CC       the epithelial secretion of electrolytes and fluid (By
CC       similarity). Also activates basolateral SLC4A4 isoform 1 to
CC       coordinate fluid and HCO3(-) secretion (PubMed:16769890). Inhibits
CC       the effect of STK39 on SLC4A4 and CFTR by recruiting PP1
CC       phosphatase which activates SLC4A4, SLC26A6 and CFTR through
CC       dephosphorylation (By similarity). Mediates the induction of
CC       SLC9A3 surface expression produced by Angiotensin-2
CC       (PubMed:20584908). Depending on the cell type, activates SLC9A3 in
CC       response to calcium or reverses SLC9A3R2-dependent calcium
CC       inhibition (PubMed:18829453). May modulate the polyadenylation
CC       state of specific mRNAs, both by controlling the subcellular
CC       location of FIP1L1 and by inhibiting PAPOLA activity, in response
CC       to a stimulus that alters its phosphorylation state
CC       (PubMed:19224921). Acts as a (dATP)-dependent inhibitor of
CC       ribonucleotide reductase large subunit RRM1, controlling the
CC       endogenous dNTP pool and ensuring normal cell cycle progression
CC       (PubMed:25237103). In vitro does not exhibit any S-adenosyl-L-
CC       homocysteine hydrolase activity (By similarity).
CC       {ECO:0000250|UniProtKB:B5DFN2, ECO:0000250|UniProtKB:Q80SW1,
CC       ECO:0000269|PubMed:16769890, ECO:0000269|PubMed:16793548,
CC       ECO:0000269|PubMed:18829453, ECO:0000269|PubMed:19224921,
CC       ECO:0000269|PubMed:20584908, ECO:0000269|PubMed:25237103}.
CC   -!- COFACTOR:
CC       Name=NAD(+); Xref=ChEBI:CHEBI:57540;
CC         Evidence={ECO:0000269|PubMed:25237103};
CC       Note=Binds 1 NAD(+) per subunit. {ECO:0000269|PubMed:25237103};
CC   -!- SUBUNIT: Forms multimers (PubMed:16793548). Forms heteromultimers
CC       with AHCYL2 (via the C-terminal region) (PubMed:19220705).
CC       Interacts (when phosphorylated) with ITPR1 (when not
CC       phosphorylated); the interaction suppresses inositol 1,4,5-
CC       trisphosphate binding to ITPR1 (PubMed:16793548). Interacts with
CC       CFTR and SLC26A6; the interactions take place once AHCYL1 is
CC       released from ITPR1 and increase CFTR and SLC26A6 activities (By
CC       similarity). Interacts with RRM1; in a phosphorylation- and
CC       (dATP)-dependent manner. Interacts (via PEST domain when
CC       phosphorylated) with SLC4A4 isoform 1 but not isoform 2; the
CC       interaction increases SLC4A4 isoform 1 activity (PubMed:16769890).
CC       Interacts (when phosphorylated) with SLC9A3; the interaction is
CC       required for SLC9A3 apical location and activity (PubMed:18829453,
CC       PubMed:20584908). Interacts (when phosphorylated) with FIP1L1; the
CC       interaction is direct and associates AHCYL1 with the CPSF complex
CC       and RNA (PubMed:19224921). Interacts with PAPOLA
CC       (PubMed:19224921). {ECO:0000250|UniProtKB:B5DFN2,
CC       ECO:0000250|UniProtKB:Q80SW1, ECO:0000269|PubMed:16769890,
CC       ECO:0000269|PubMed:16793548, ECO:0000269|PubMed:18829453,
CC       ECO:0000269|PubMed:19220705, ECO:0000269|PubMed:19224921,
CC       ECO:0000269|PubMed:20584908, ECO:0000269|PubMed:25237103}.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-2371423, EBI-2371423;
CC       P55957:BID; NbExp=3; IntAct=EBI-2371423, EBI-519672;
CC       P55957-2:BID; NbExp=3; IntAct=EBI-2371423, EBI-10215147;
CC       P42773:CDKN2C; NbExp=8; IntAct=EBI-2371423, EBI-711290;
CC       Q9UI36-2:DACH1; NbExp=9; IntAct=EBI-2371423, EBI-10186082;
CC       P55040:GEM; NbExp=7; IntAct=EBI-2371423, EBI-744104;
CC       A4D127:MEOX2; NbExp=3; IntAct=EBI-2371423, EBI-10172134;
CC       O60437:PPL; NbExp=3; IntAct=EBI-2371423, EBI-368321;
CC       O00233:PSMD9; NbExp=3; IntAct=EBI-2371423, EBI-750973;
CC       Q9UHI7:SLC23A1; NbExp=3; IntAct=EBI-2371423, EBI-1759386;
CC       O94993:SOX30; NbExp=3; IntAct=EBI-2371423, EBI-742973;
CC       P04608:tat (xeno); NbExp=5; IntAct=EBI-2371423, EBI-6164389;
CC       P49910:ZNF165; NbExp=4; IntAct=EBI-2371423, EBI-741694;
CC       Q53Z40:ZNF165; NbExp=5; IntAct=EBI-2371423, EBI-10186058;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum
CC       {ECO:0000250|UniProtKB:Q80SW1}. Cytoplasm, cytosol
CC       {ECO:0000250|UniProtKB:Q80SW1}. Microsome
CC       {ECO:0000250|UniProtKB:Q80SW1}. Apical cell membrane
CC       {ECO:0000250|UniProtKB:B5DFN2}. Note=Associates with membranes
CC       when phosphorylated, probably through interaction with ITPR1.
CC       {ECO:0000250|UniProtKB:Q80SW1}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O43865-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O43865-2; Sequence=VSP_021751;
CC         Note=Derived from EST data. Contains a N-acetylmethionine at
CC         position 1. {ECO:0000244|PubMed:22814378};
CC   -!- TISSUE SPECIFICITY: Expressed in dendritic cells.
CC       {ECO:0000269|PubMed:11904675}.
CC   -!- DEVELOPMENTAL STAGE: Expression increases markedly during
CC       activation of blood and skin DC (Langerhans cells), but is
CC       diminished in terminally differentiated tonsil DC.
CC       {ECO:0000269|PubMed:11904675}.
CC   -!- DOMAIN: The PEST region is essential for the interaction with
CC       ITPR1, and, when phosphorylated, is also the RRM1-binding region.
CC       The PDZ-binding region is required for maximal interaction with
CC       ITPR1 and is also responsible for the IP3-insensitive interaction
CC       with ITPR1 (By similarity). {ECO:0000250|UniProtKB:Q80SW1,
CC       ECO:0000269|PubMed:25237103}.
CC   -!- PTM: Phosphorylated at Ser/Thr residues between Ser-68 and Thr-72
CC       in the PEST region: required for interaction with dATP-bound RRM1
CC       and ITPR1. Phosphorylation at Ser-68 by PRKD1 and CAMK4 is
CC       required for further phosphorylations by CSNK1A1
CC       (PubMed:16793548). Phosphorylation is induced by oxidative stress
CC       (PubMed:19224921). Probably phosphorylated by CAMK2A;
CC       phosphorylation at Ser-68 may be required for interaction with
CC       SLC9A3 (PubMed:20584908). {ECO:0000269|PubMed:16793548,
CC       ECO:0000269|PubMed:19224921, ECO:0000269|PubMed:25237103,
CC       ECO:0000305|PubMed:20584908}.
CC   -!- MISCELLANEOUS: Ablation of expression in HeLa cells causes
CC       imbalanced dNTP pools and altered cell cycle progression.
CC       {ECO:0000269|PubMed:25237103}.
CC   -!- SIMILARITY: Belongs to the adenosylhomocysteinase family.
CC       {ECO:0000305}.
CC   -!- CAUTION: In spite of its similarity with AHCY, which catalyzes the
CC       reversible hydrolysis of S-adenosyl-L-homocysteine to adenosine
CC       and homocysteine, recombinant AHCYL1 expressed in bacteria shows
CC       no hydrolysase activity, nor does it affect the enzyme activity of
CC       AHCY. {ECO:0000250|UniProtKB:Q80SW1}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC01960.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BI460083; Type=Frameshift; Positions=Several; Evidence={ECO:0000305};
CC       Sequence=CAB43223.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF315687; AAL26869.1; -; mRNA.
DR   EMBL; AL036027; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK303690; BAG64680.1; -; mRNA.
DR   EMBL; AK316110; BAH14481.1; -; mRNA.
DR   EMBL; AL049954; CAB43223.2; ALT_INIT; mRNA.
DR   EMBL; AL772411; CAH70965.1; -; Genomic_DNA.
DR   EMBL; AL772411; CAH70966.1; -; Genomic_DNA.
DR   EMBL; CH471122; EAW56426.1; -; Genomic_DNA.
DR   EMBL; BC007576; AAH07576.3; -; mRNA.
DR   EMBL; BC010681; AAH10681.3; -; mRNA.
DR   EMBL; BC016942; AAH16942.3; -; mRNA.
DR   EMBL; BC065254; AAH65254.2; -; mRNA.
DR   EMBL; BC095476; AAH95476.2; -; mRNA.
DR   EMBL; BC110896; AAI10897.2; -; mRNA.
DR   EMBL; BI460083; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; U82761; AAC01960.1; ALT_INIT; mRNA.
DR   EMBL; AU279527; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; T19009; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BK005418; DAA05763.1; -; mRNA.
DR   EMBL; BK005417; DAA05762.1; -; mRNA.
DR   CCDS; CCDS55620.1; -. [O43865-2]
DR   CCDS; CCDS818.1; -. [O43865-1]
DR   PIR; T08681; T08681.
DR   RefSeq; NP_001229602.1; NM_001242673.1. [O43865-2]
DR   RefSeq; NP_001229603.1; NM_001242674.1. [O43865-2]
DR   RefSeq; NP_001229604.1; NM_001242675.1. [O43865-2]
DR   RefSeq; NP_001229605.1; NM_001242676.1. [O43865-2]
DR   RefSeq; NP_006612.2; NM_006621.5. [O43865-1]
DR   UniGene; Hs.743973; -.
DR   PDB; 3MTG; X-ray; 2.64 A; A/B=89-530.
DR   PDBsum; 3MTG; -.
DR   ProteinModelPortal; O43865; -.
DR   SMR; O43865; -.
DR   BioGrid; 115987; 155.
DR   IntAct; O43865; 31.
DR   STRING; 9606.ENSP00000358814; -.
DR   iPTMnet; O43865; -.
DR   PhosphoSitePlus; O43865; -.
DR   BioMuta; AHCYL1; -.
DR   EPD; O43865; -.
DR   MaxQB; O43865; -.
DR   PaxDb; O43865; -.
DR   PeptideAtlas; O43865; -.
DR   PRIDE; O43865; -.
DR   DNASU; 10768; -.
DR   Ensembl; ENST00000359172; ENSP00000352092; ENSG00000168710. [O43865-2]
DR   Ensembl; ENST00000369799; ENSP00000358814; ENSG00000168710. [O43865-1]
DR   Ensembl; ENST00000393614; ENSP00000377238; ENSG00000168710. [O43865-2]
DR   GeneID; 10768; -.
DR   KEGG; hsa:10768; -.
DR   UCSC; uc001dyx.4; human. [O43865-1]
DR   CTD; 10768; -.
DR   DisGeNET; 10768; -.
DR   GeneCards; AHCYL1; -.
DR   HGNC; HGNC:344; AHCYL1.
DR   HPA; HPA042589; -.
DR   MIM; 607826; gene.
DR   neXtProt; NX_O43865; -.
DR   OpenTargets; ENSG00000168710; -.
DR   PharmGKB; PA24637; -.
DR   eggNOG; KOG1370; Eukaryota.
DR   eggNOG; COG0499; LUCA.
DR   GeneTree; ENSGT00390000003626; -.
DR   HOGENOM; HOG000227986; -.
DR   HOVERGEN; HBG005041; -.
DR   InParanoid; O43865; -.
DR   KO; K01251; -.
DR   OMA; PVKKQIQ; -.
DR   OrthoDB; EOG091G06EB; -.
DR   PhylomeDB; O43865; -.
DR   TreeFam; TF300415; -.
DR   Reactome; R-HSA-112043; PLC beta mediated events.
DR   Reactome; R-HSA-1489509; DAG and IP3 signaling.
DR   Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis.
DR   Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization.
DR   Reactome; R-HSA-422356; Regulation of insulin secretion.
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation.
DR   Reactome; R-HSA-5578775; Ion homeostasis.
DR   Reactome; R-HSA-5607763; CLEC7A (Dectin-1) induces NFAT activation.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SIGNOR; O43865; -.
DR   ChiTaRS; AHCYL1; human.
DR   EvolutionaryTrace; O43865; -.
DR   GeneWiki; AHCYL1; -.
DR   GenomeRNAi; 10768; -.
DR   PMAP-CutDB; O43865; -.
DR   PRO; PR:O43865; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000168710; -.
DR   CleanEx; HS_AHCYL1; -.
DR   ExpressionAtlas; O43865; baseline and differential.
DR   Genevisible; O43865; HS.
DR   GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016787; F:hydrolase activity; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0038166; P:angiotensin-activated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0042045; P:epithelial fluid transport; IEA:Ensembl.
DR   GO; GO:0006378; P:mRNA polyadenylation; IDA:UniProtKB.
DR   GO; GO:0006730; P:one-carbon metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0010765; P:positive regulation of sodium ion transport; IMP:UniProtKB.
DR   GO; GO:0006611; P:protein export from nucleus; IEA:Ensembl.
DR   GO; GO:0044070; P:regulation of anion transport; IEA:Ensembl.
DR   GO; GO:1903779; P:regulation of cardiac conduction; TAS:Reactome.
DR   GO; GO:0032412; P:regulation of ion transmembrane transporter activity; IMP:UniProtKB.
DR   GO; GO:0031440; P:regulation of mRNA 3'-end processing; IDA:UniProtKB.
DR   GO; GO:0051592; P:response to calcium ion; IDA:UniProtKB.
DR   GO; GO:0033353; P:S-adenosylmethionine cycle; IBA:GO_Central.
DR   CDD; cd00401; SAHH; 1.
DR   InterPro; IPR000043; Adenosylhomocysteinase-like.
DR   InterPro; IPR015878; Ado_hCys_hydrolase_NAD-bd.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   InterPro; IPR020082; S-Ado-L-homoCys_hydrolase_CS.
DR   PANTHER; PTHR23420; PTHR23420; 1.
DR   Pfam; PF05221; AdoHcyase; 1.
DR   Pfam; PF00670; AdoHcyase_NAD; 1.
DR   PIRSF; PIRSF001109; Ad_hcy_hydrolase; 1.
DR   SMART; SM00996; AdoHcyase; 1.
DR   SMART; SM00997; AdoHcyase_NAD; 1.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   TIGRFAMs; TIGR00936; ahcY; 1.
DR   PROSITE; PS00738; ADOHCYASE_1; 1.
DR   PROSITE; PS00739; ADOHCYASE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cell membrane;
KW   Complete proteome; Cytoplasm; Endoplasmic reticulum; Membrane;
KW   Microsome; NAD; One-carbon metabolism; Phosphoprotein;
KW   Reference proteome; RNA-binding.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:21406692}.
FT   CHAIN         2    530       S-adenosylhomocysteine hydrolase-like
FT                                protein 1.
FT                                /FTId=PRO_0000116908.
FT   NP_BIND     318    322       NAD. {ECO:0000269|PubMed:25237103}.
FT   NP_BIND     397    399       NAD. {ECO:0000269|PubMed:25237103}.
FT   REGION       65     92       PEST. {ECO:0000269|PubMed:25237103}.
FT   REGION      281    448       NAD binding. {ECO:0000250}.
FT   REGION      520    530       PDZ-binding. {ECO:0000250}.
FT   BINDING     155    155       Substrate. {ECO:0000250}.
FT   BINDING     229    229       Substrate. {ECO:0000250}.
FT   BINDING     254    254       Substrate. {ECO:0000250}.
FT   BINDING     284    284       Substrate. {ECO:0000250}.
FT   BINDING     288    288       Substrate. {ECO:0000250}.
FT   BINDING     341    341       NAD. {ECO:0000269|PubMed:25237103}.
FT   BINDING     376    376       NAD. {ECO:0000269|PubMed:25237103}.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES       2      2       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      40     40       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q80SW1}.
FT   MOD_RES      68     68       Phosphoserine.
FT                                {ECO:0000305|PubMed:16793548,
FT                                ECO:0000305|PubMed:19220705}.
FT   MOD_RES      71     71       Phosphoserine.
FT                                {ECO:0000305|PubMed:16793548,
FT                                ECO:0000305|PubMed:19220705}.
FT   MOD_RES      74     74       Phosphoserine.
FT                                {ECO:0000305|PubMed:19220705}.
FT   MOD_RES      77     77       Phosphoserine.
FT                                {ECO:0000305|PubMed:19220705}.
FT   MOD_RES      84     84       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q80SW1}.
FT   MOD_RES     391    391       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   VAR_SEQ       1     47       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:12878157,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17974005,
FT                                ECO:0000303|PubMed:7782076}.
FT                                /FTId=VSP_021751.
FT   MUTAGEN      52     52       T->A: No effect on interaction with
FT                                SLC4A4. {ECO:0000269|PubMed:16769890}.
FT   MUTAGEN      58     58       T->A: No effect on interaction with
FT                                SLC4A4. {ECO:0000269|PubMed:16769890}.
FT   MUTAGEN      62     62       S->A: No effect on interaction with
FT                                SLC4A4. No effect on interaction with
FT                                FIP1L1. {ECO:0000269|PubMed:16769890,
FT                                ECO:0000269|PubMed:19224921}.
FT   MUTAGEN      64     64       S->A: No effect on interaction with
FT                                ITPR1. No effect on phosphorylation. No
FT                                effect on interaction with SLC4A4. No
FT                                effect on interaction with FIP1L1.
FT                                {ECO:0000269|PubMed:16769890,
FT                                ECO:0000269|PubMed:16793548,
FT                                ECO:0000269|PubMed:19224921}.
FT   MUTAGEN      66     66       S->A: Slightly decreases interaction with
FT                                ITPR1. Slightly decreases
FT                                phosphorylation. No effect on interaction
FT                                with SLC4A4. Abolishes interaction with
FT                                FIP1L1. {ECO:0000269|PubMed:16769890,
FT                                ECO:0000269|PubMed:16793548,
FT                                ECO:0000269|PubMed:19224921}.
FT   MUTAGEN      68     68       S->A: Abolishes interaction with ITPR1.
FT                                Highly decreases phosphorylation. No
FT                                effect on formation of multimers.
FT                                Abolishes interaction with SLC4A4.
FT                                Abolishes interaction with FIP1L1. Highly
FT                                decreases interaction with SLC9A3. Highly
FT                                decreases interaction with SLC9A3; when
FT                                associated whith A-71 and A-74.
FT                                {ECO:0000269|PubMed:16769890,
FT                                ECO:0000269|PubMed:16793548,
FT                                ECO:0000269|PubMed:19224921,
FT                                ECO:0000269|PubMed:20584908}.
FT   MUTAGEN      70     70       S->A: Highly decreases interaction with
FT                                ITPR1. No effect on phosphorylation. No
FT                                effect on interaction with SLC4A4.
FT                                Abolishes interaction with FIP1L1.
FT                                {ECO:0000269|PubMed:16769890,
FT                                ECO:0000269|PubMed:16793548,
FT                                ECO:0000269|PubMed:19224921}.
FT   MUTAGEN      71     71       S->A: Abolishes interaction with ITPR1.
FT                                Highly decreases phosphorylation.
FT                                Abolishes interaction with SLC4A4.
FT                                Abolishes interaction with FIP1L1. Highly
FT                                decreases interaction with SLC9A3; when
FT                                associated whith A-68 and A-74.
FT                                {ECO:0000269|PubMed:16769890,
FT                                ECO:0000269|PubMed:16793548,
FT                                ECO:0000269|PubMed:19224921,
FT                                ECO:0000269|PubMed:20584908}.
FT   MUTAGEN      72     72       T->A: Highly decreases interaction with
FT                                ITPR1. Slightly increases
FT                                phosphorylation. No effect on interaction
FT                                with SLC4A4. Highly decreases interaction
FT                                with FIP1L1.
FT                                {ECO:0000269|PubMed:16769890,
FT                                ECO:0000269|PubMed:16793548,
FT                                ECO:0000269|PubMed:19224921}.
FT   MUTAGEN      74     74       S->G: Abolishes interaction with ITPR1.
FT                                Slightly decreases phosphorylation.
FT                                Strongly decreases interaction with
FT                                SLC4A4. Abolishes interaction with
FT                                FIP1L1. Highly decreases interaction with
FT                                SLC9A3; when associated whith A-68 and A-
FT                                71. {ECO:0000269|PubMed:16769890,
FT                                ECO:0000269|PubMed:16793548,
FT                                ECO:0000269|PubMed:19224921,
FT                                ECO:0000269|PubMed:20584908}.
FT   MUTAGEN      76     76       S->G: No effect on interaction with
FT                                ITPR1. No effect on phosphorylation. No
FT                                effect on interaction with SLC4A4. No
FT                                effect on interaction with FIP1L1.
FT                                {ECO:0000269|PubMed:16769890,
FT                                ECO:0000269|PubMed:16793548,
FT                                ECO:0000269|PubMed:19224921}.
FT   MUTAGEN      77     77       S->A: Highly decreases interaction with
FT                                ITPR1. Slightly decreases
FT                                phosphorylation. Strongly decreases
FT                                interaction with SLC4A4. Abolishes
FT                                interaction with FIP1L1.
FT                                {ECO:0000269|PubMed:16769890,
FT                                ECO:0000269|PubMed:16793548,
FT                                ECO:0000269|PubMed:19224921}.
FT   MUTAGEN      80     80       S->A: No effect on interaction with
FT                                SLC4A4. Highly decreases interaction with
FT                                FIP1L1. {ECO:0000269|PubMed:16769890,
FT                                ECO:0000269|PubMed:16793548,
FT                                ECO:0000269|PubMed:19224921}.
FT   MUTAGEN      82     82       T->A: No effect on interaction with
FT                                ITPR1. No effect on phosphorylation. No
FT                                effect on interaction with SLC4A4.
FT                                Decreases interaction with FIP1L1.
FT                                {ECO:0000269|PubMed:16769890,
FT                                ECO:0000269|PubMed:16793548,
FT                                ECO:0000269|PubMed:19224921}.
FT   MUTAGEN      84     84       S->A: Slightly decreases interaction with
FT                                ITPR1. No effect on phosphorylation. No
FT                                effect on interaction with SLC4A4.
FT                                Decreases interaction with FIP1L1.
FT                                {ECO:0000269|PubMed:16769890,
FT                                ECO:0000269|PubMed:16793548,
FT                                ECO:0000269|PubMed:19224921}.
FT   MUTAGEN      85     85       S->A: Slightly decreases interaction with
FT                                ITPR1. No effect on phosphorylation. No
FT                                effect on interaction with SLC4A4.
FT                                Decreases interaction with FIP1L1.
FT                                {ECO:0000269|PubMed:16769890,
FT                                ECO:0000269|PubMed:16793548,
FT                                ECO:0000269|PubMed:19224921}.
FT   MUTAGEN      90     90       S->A: No effect on interaction with
FT                                ITPR1. No effect on phosphorylation. No
FT                                effect on interaction with SLC4A4. No
FT                                effect on interaction with FIP1L1.
FT                                {ECO:0000269|PubMed:16769890,
FT                                ECO:0000269|PubMed:16793548,
FT                                ECO:0000269|PubMed:19224921}.
FT   MUTAGEN      97     97       T->A: No effect on interaction with
FT                                ITPR1. No effect on interaction with
FT                                SLC4A4. No effect on interaction with
FT                                FIP1L1. {ECO:0000269|PubMed:16769890,
FT                                ECO:0000269|PubMed:16793548,
FT                                ECO:0000269|PubMed:19224921}.
FT   CONFLICT     94     94       K -> M (in Ref. 9; T19009).
FT                                {ECO:0000305}.
FT   CONFLICT     99     99       S -> F (in Ref. 9; T19009).
FT                                {ECO:0000305}.
FT   HELIX       113    124       {ECO:0000244|PDB:3MTG}.
FT   HELIX       128    137       {ECO:0000244|PDB:3MTG}.
FT   TURN        142    145       {ECO:0000244|PDB:3MTG}.
FT   STRAND      147    152       {ECO:0000244|PDB:3MTG}.
FT   HELIX       156    167       {ECO:0000244|PDB:3MTG}.
FT   STRAND      171    175       {ECO:0000244|PDB:3MTG}.
FT   STRAND      177    180       {ECO:0000244|PDB:3MTG}.
FT   HELIX       184    193       {ECO:0000244|PDB:3MTG}.
FT   STRAND      196    198       {ECO:0000244|PDB:3MTG}.
FT   HELIX       205    216       {ECO:0000244|PDB:3MTG}.
FT   STRAND      224    231       {ECO:0000244|PDB:3MTG}.
FT   HELIX       232    240       {ECO:0000244|PDB:3MTG}.
FT   HELIX       242    245       {ECO:0000244|PDB:3MTG}.
FT   STRAND      249    253       {ECO:0000244|PDB:3MTG}.
FT   HELIX       256    265       {ECO:0000244|PDB:3MTG}.
FT   TURN        266    269       {ECO:0000244|PDB:3MTG}.
FT   STRAND      275    277       {ECO:0000244|PDB:3MTG}.
FT   HELIX       282    293       {ECO:0000244|PDB:3MTG}.
FT   HELIX       299    305       {ECO:0000244|PDB:3MTG}.
FT   STRAND      313    317       {ECO:0000244|PDB:3MTG}.
FT   HELIX       321    333       {ECO:0000244|PDB:3MTG}.
FT   STRAND      336    340       {ECO:0000244|PDB:3MTG}.
FT   HELIX       344    352       {ECO:0000244|PDB:3MTG}.
FT   HELIX       360    362       {ECO:0000244|PDB:3MTG}.
FT   TURN        363    366       {ECO:0000244|PDB:3MTG}.
FT   STRAND      368    372       {ECO:0000244|PDB:3MTG}.
FT   HELIX       382    387       {ECO:0000244|PDB:3MTG}.
FT   STRAND      392    396       {ECO:0000244|PDB:3MTG}.
FT   TURN        400    403       {ECO:0000244|PDB:3MTG}.
FT   HELIX       406    409       {ECO:0000244|PDB:3MTG}.
FT   STRAND      415    420       {ECO:0000244|PDB:3MTG}.
FT   STRAND      423    427       {ECO:0000244|PDB:3MTG}.
FT   STRAND      433    437       {ECO:0000244|PDB:3MTG}.
FT   HELIX       438    440       {ECO:0000244|PDB:3MTG}.
FT   HELIX       444    446       {ECO:0000244|PDB:3MTG}.
FT   HELIX       452    471       {ECO:0000244|PDB:3MTG}.
FT   STRAND      479    482       {ECO:0000244|PDB:3MTG}.
FT   HELIX       486    496       {ECO:0000244|PDB:3MTG}.
FT   HELIX       497    500       {ECO:0000244|PDB:3MTG}.
FT   HELIX       509    514       {ECO:0000244|PDB:3MTG}.
FT   STRAND      519    521       {ECO:0000244|PDB:3MTG}.
SQ   SEQUENCE   530 AA;  58951 MW;  974D23361A245D04 CRC64;
     MSMPDAMPLP GVGEELKQAK EIEDAEKYSF MATVTKAPKK QIQFADDMQE FTKFPTKTGR
     RSLSRSISQS STDSYSSAAS YTDSSDDEVS PREKQQTNSK GSSNFCVKNI KQAEFGRREI
     EIAEQDMSAL ISLRKRAQGE KPLAGAKIVG CTHITAQTAV LIETLCALGA QCRWSACNIY
     STQNEVAAAL AEAGVAVFAW KGESEDDFWW CIDRCVNMDG WQANMILDDG GDLTHWVYKK
     YPNVFKKIRG IVEESVTGVH RLYQLSKAGK LCVPAMNVND SVTKQKFDNL YCCRESILDG
     LKRTTDVMFG GKQVVVCGYG EVGKGCCAAL KALGAIVYIT EIDPICALQA CMDGFRVVKL
     NEVIRQVDVV ITCTGNKNVV TREHLDRMKN SCIVCNMGHS NTEIDVTSLR TPELTWERVR
     SQVDHVIWPD GKRVVLLAEG RLLNLSCSTV PTFVLSITAT TQALALIELY NAPEGRYKQD
     VYLLPKKMDE YVASLHLPSF DAHLTELTDD QAKYLGLNKN GPFKPNYYRY
//
